Rivaroxaban Zero Growth
Interesting on the 4Q call JNJ never mentioned Xarelto, nor did any analyst ask about its sales.
Digging into the detailed income statement, sales grew from $608m in 2018 4Q to $609m in 4Q 2019. In other words, zero growth for 2019 4Q for Xarelto on a dollar basis. In fact year over year (2019 vs 2018) Xarelto is down 6.6% from $2,477m to $2,313m. All of the sales figures are US only as Bayer has the rights internationally.
In prior qtrs JNJ had mentioned pricing changes and coverage gaps that negatively impacted sales while maintaining the number of Rx's actually grew. Now with no mention at all this qtr, it appears apixaban is gaining and taking market share from rivaroxaban.